Figure 8.
Figure 8. Coagulation testing and antibody studies in dog E57. (A) Canine F.IX antigen levels as a function of time after injection. Arrows denote time points at which cyclophosphamide was administered; asterisks denote infusions of canine plasma. F.IX level peaked 55 days after injection and fell rapidly after cyclophosphamide was discontinued. (B) WBCT as a function of time after injection. The WBCT fell to the normal range about 1 week after vector injection. Levels remained reduced into or near the normal range until approximately day 70 when they were again prolonged. (C) Bethesda titer as a function of time after injection. Bethesda titer was undetectable until day 77. The titer was initially low but subsequently rose to approximately 8 BU. (D) Anti–F.IX antibody subclasses as a function of time. Both subclasses remain at baseline through the duration of cyclophosphamide therapy, but IgG1 rises rapidly, and IgG2 more slowly, after cyclophosphamide discontinuation.

Coagulation testing and antibody studies in dog E57. (A) Canine F.IX antigen levels as a function of time after injection. Arrows denote time points at which cyclophosphamide was administered; asterisks denote infusions of canine plasma. F.IX level peaked 55 days after injection and fell rapidly after cyclophosphamide was discontinued. (B) WBCT as a function of time after injection. The WBCT fell to the normal range about 1 week after vector injection. Levels remained reduced into or near the normal range until approximately day 70 when they were again prolonged. (C) Bethesda titer as a function of time after injection. Bethesda titer was undetectable until day 77. The titer was initially low but subsequently rose to approximately 8 BU. (D) Anti–F.IX antibody subclasses as a function of time. Both subclasses remain at baseline through the duration of cyclophosphamide therapy, but IgG1 rises rapidly, and IgG2 more slowly, after cyclophosphamide discontinuation.

Close Modal

or Create an Account

Close Modal
Close Modal